Protagenic Therapeutics Inc. Watch

from 8-K 15 pages Placement Agent Common Stock Purchase Warrant Protagenic Therapeutics, Inc

from 8-K 16 pages Series B Common Stock Purchase Warrant Protagenic Therapeutics, Inc

from 8-K 16 pages Series a Common Stock Purchase Warrant Protagenic Therapeutics, Inc

from S-3 49 pages Protagenic Therapeutics, Inc. Company and [Trustee] Trustee Indenture Dated as of [●], 20[●] Subordinated Debt Securities

from S-3 51 pages Protagenic Therapeutics, Inc. Issuer and [Trustee] Trustee Indenture Dated as of [●], 20[●] Senior Debt Securities

from 10-K 4 pages The Following Description Is Intended as a Summary of Our Third Amended and Restated Certificate of Incorporation (Which We Refer to as Our “Charter”) and Our Bylaws, and to the Applicable Provisions of the Delaware General Corporation Law. Because the Following Is Only a Summary, It Does Not Contain All of the Information That May Be Important to You. for a Complete Description, You Should Refer to Our Charter and Bylaws. Our Current Certificate of Incorporation Authorizes US to Issue: ● 100,000,000 Shares of Common Stock, Par Value $0.0001 Per Share; and ● 20,000,000 Shares of Preferred Stock, Par Value $0.000001 Per Share, of Which 18,000,000 Shares Have Been Designated as Series B Preferred Stock and the Remainder of Which Have Not Been Designated. as of March 31, 2023, There Were 4,321,445 Shares of Common Stock Outstanding and 0 Shares of Series B Preferred Stock Outstanding. Common Stock Voting. the Holders of Our Common Stock Are Entitled to One Vote for Each Share Held of Record on All Matters on Which the Holders Are Entitled to Vote (Or Consent Pursuant to Written Consent). Dividends. the Holders of Our Common Stock Are Entitled to Receive, Ratably, Dividends Only If, When and as Declared by Our Board of Directors Out of Funds Legally Available Therefor and After Provision Is Made for Each Class of Capital Stock Having Preference Over the Common Stock

from 10-K 4 pages The Following Description Is Intended as a Summary of Our Third Amended and Restated Certificate of Incorporation (Which We Refer to as Our “Charter”) and Our Bylaws, and to the Applicable Provisions of the Delaware General Corporation Law. Because the Following Is Only a Summary, It Does Not Contain All of the Information That May Be Important to You. for a Complete Description, You Should Refer to Our Charter and Bylaws. Our Current Certificate of Incorporation Authorizes US to Issue: ● 100,000,000 Shares of Common Stock, Par Value $0.0001 Per Share; and ● 20,000,000 Shares of Preferred Stock, Par Value $0.000001 Per Share, of Which 18,000,000 Shares Have Been Designated as Series B Preferred Stock and the Remainder of Which Have Not Been Designated. as of March 31, 2023, There Were 4,321,445 Shares of Common Stock Outstanding and 0 Shares of Series B Preferred Stock Outstanding. Common Stock Voting. the Holders of Our Common Stock Are Entitled to One Vote for Each Share Held of Record on All Matters on Which the Holders Are Entitled to Vote (Or Consent Pursuant to Written Consent). Dividends. the Holders of Our Common Stock Are Entitled to Receive, Ratably, Dividends Only If, When and as Declared by Our Board of Directors Out of Funds Legally Available Therefor and After Provision Is Made for Each Class of Capital Stock Having Preference Over the Common Stock

from 10-K 4 pages The Following Description Is Intended as a Summary of Our Third Amended and Restated Certificate of Incorporation (Which We Refer to as Our “Charter”) and Our Bylaws, and to the Applicable Provisions of the Delaware General Corporation Law. Because the Following Is Only a Summary, It Does Not Contain All of the Information That May Be Important to You. for a Complete Description, You Should Refer to Our Charter and Bylaws. Our Current Certificate of Incorporation Authorizes US to Issue: ● 100,000,000 Shares of Common Stock, Par Value $0.0001 Per Share; and ● 20,000,000 Shares of Preferred Stock, Par Value $0.000001 Per Share, of Which 18,000,000 Shares Have Been Designated as Series B Preferred Stock and the Remainder of Which Have Not Been Designated. as of March 31, 2022, There Were 17,253,278 Shares of Common Stock Outstanding and 0 Shares of Series B Preferred Stock Outstanding. Common Stock Voting. the Holders of Our Common Stock Are Entitled to One Vote for Each Share Held of Record on All Matters on Which the Holders Are Entitled to Vote (Or Consent Pursuant to Written Consent). Dividends. the Holders of Our Common Stock Are Entitled to Receive, Ratably, Dividends Only If, When and as Declared by Our Board of Directors Out of Funds Legally Available Therefor and After Provision Is Made for Each Class of Capital Stock Having Preference Over the Common Stock

from S-3 49 pages Protagenic Therapeutics, Inc. Company and [Trustee] Trustee Indenture Dated as of [●], 20[●] Subordinated Debt Securities

from S-3 51 pages Protagenic Therapeutics, Inc. Issuer and [Trustee] Trustee Indenture Dated as of [●], 20[●] Senior Debt Securities

from 10-K 3 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

from S-8 10 pages Protagenic Therapeutics, Inc. Nonqualified Stock Option Agreement

from S-8 10 pages Protagenic Therapeutics, Inc. Nonqualified Stock Option Agreement

from S-8 10 pages Protagenic Therapeutics, Inc. Nonqualified Stock Option Agreement

from 8-K 13 pages Form of Brokers Warrant

from 8-K 13 pages Warrant to Purchase Shares of Common Stock

from 8-K 13 pages Warrant to Purchase Shares of Common Stock

from 8-K 13 pages Warrant to Purchase Shares of Common Stock

from 8-K 13 pages Warrant to Purchase Shares of Common Stock

from 8-K 16 pages Warrant to Purchase Shares of Series B Preferred Stock or Common Stock